Advocate Christ Medical Center Extends Leadership in Heart Care with Adoption of Genesis Robotic Technology
May 23 2023 - 08:46AM
Stereotaxis (NYSE: STXS), the global leader in robotic technologies
for the treatment of cardiac arrhythmias, today announced the first
treatment of patients with a newly launched Genesis Robotic
Magnetic Navigation (RMN) system at Advocate Christ Medical Center
in Chicago, Illinois.
Advocate Christ Medical Center, a part of
Advocate Health, is the leading provider of robotic heart rhythm
care in the Midwest. Electrophysiologists at the hospital have
treated over 2,000 patients using advanced robotic technology. The
hospital is now among the first in the world, and the first in
Chicago, to offer the Genesis RMN system to patients.
"At Advocate Christ, we take pride in providing
the highest quality care," said Dr. Jeffrey Neiger, Cardiac
Electrophysiologist at Advocate Christ Medical Center. "For more
than a decade, our electrophysiology team has leveraged the
precision and safety of robotics when treating our cardiac
patients. With the adoption of Genesis, we are extending our
commitment to that technological and clinical leadership."
Robotic Magnetic Navigation introduces the
benefits of robotic precision and safety to cardiac ablation, a
common minimally invasive procedure to treat arrhythmias. Tens of
millions of individuals worldwide suffer from arrhythmias –
abnormal heart rhythms that result when the heart beats too
quickly, too slowly, or with an irregular pattern. When left
untreated, arrhythmias may significantly increase the risk of
stroke, heart failure, and sudden cardiac arrest.
"We are excited to continue our partnership with
Advocate Christ in advancing the frontiers of patient care and
clinical science in cardiology," said David Fischel, Chairman
and CEO of Stereotaxis. "We look forward to working with them
in ensuring the best possible heart care is available to the
Chicago community."
About StereotaxisStereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical
robotics for minimally invasive endovascular intervention. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2023 to Mar 2024